S-1/A: Synergy CHC Corp. Files Amendment No. 1 to Form S-1 for Proposed IPO

Synergy CHC Corp. has filed an amendment to its S-1 registration statement, outlining details for a proposed IPO of its common stock.

Summary

• Synergy CHC Corp. has filed Amendment No. 1 to its Form S-1 registration statement with the SEC for a proposed IPO.
• The company plans to offer shares of its common stock to the public.
• The initial public offering price is estimated to be between $ and $ per share.
• Synergy CHC Corp. has applied to list its common stock on the Nasdaq Capital Market under the symbol SNYR.
• Roth Capital Partners is acting as the underwriter for the offering.
• Following the IPO, officers and directors will hold approximately 61% of the voting power.
• The company intends to use the net proceeds for general corporate purposes, including accelerating the growth of its current brands through advertising and other methods.
• The company's flagship brand, FOCUSfactor, is a brain health nutritional supplement, while Flat Tummy offers lifestyle and wellness products.
• The company plans to expand internationally into Taiwan and Mexico in the second quarter of 2025 and in Australia and Asia in the first quarter of 2026.
• The lender under the Amended and Restated Loan Agreement is Knight Therapeutics (Barbados) Inc., and an affiliate of Knight is also the beneficial owner of approximately 19.6% of the company's outstanding common stock.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and plans for expansion, but also acknowledges existing debt and competitive pressures.

Positives

• FOCUSfactor net revenue for the year ended December 31, 2023 was $37.2 million, a 17.0% increase over FOCUSfactor net revenue for the year ended December 31, 2022 of $31.8 million.
• Net revenue for the three months ended March 31, 2024 was $9.4 million, an increase of $1.4 million, or 18.2% over net revenue for the three months ended March 31, 2023.
• The company has grown its FOCUSfactor brand from 3 SKUs at acquisition to over 34 SKUs, and its Flat Tummy Brand from 1 SKU to 13 SKUs.
• The company's asset-light business model allows it to scale quickly and profitably while satisfying growing demand.

Negatives

• The company's capital structure following the acquisitions of its key brands in 2015 has been highly levered.
• At December 31, 2023 the company had a working capital deficit of $2.2 million.
• At March 31, 2024 the company had a working capital deficit of $0.08 million.

Risks

• The company operates in a highly competitive industry.
• The company's sales growth is dependent upon maintaining its relationships with a small number of existing large customers.
• If the company's outside suppliers and manufacturers fail to supply products in sufficient quantities and in a timely fashion, the business could suffer.
• The company plans to expand into additional international markets, which will expose it to significant operational risks.
• The company may experience product recalls, withdrawals or seizures, which could materially and adversely affect its business, financial condition and results of operations.

Future Outlook

Following the completion of this offering, the company intends to use the proceeds for general corporate purposes, including to accelerate the growth of its current brands through advertising and other methods. The company plans to expand internationally into Taiwan and Mexico in the second quarter of 2025 and in Australia and Asia in the first quarter of 2026.

Management Comments

• Management's philosophy is to acquire promising brands that fit within our health, beauty and lifestyle offerings, and apply our marketing and distribution strategies to develop brands to their full potential.
• We believe we are adept at identifying promising opportunities that build out and complement our core brand portfolio.

Industry Context

The U.S. nutritional supplements retail industry is large and highly fragmented with few barriers to entry. The brain health segment is slated to grow at 8% per year in the United States and 13% per year globally, according to Grand View Research.

Comparison to Industry Standards

• The brain health segment is slated to grow at 8% per year in the United States and 13% per year globally, according to Grand View Research.
• FOCUSfactor's growth in the year ended December 31, 2023 was 17% year-over-year, significantly outpacing the overall brain health supplement market.
• The weight management and wellbeing market, which Flat Tummy competes in, was estimated to be an $11.3 billion global market in 2022, with forecasted growth of 4.0% annually from 2023 to 2032, according to Business Research Insights.

Legal Proceedings

• In August 2022, the company filed a lawsuit against one of its contract manufacturers, which was settled during December 2023, resulting in a net gain to the company of $2,235,986.
• On July 28, 2023, L.O.D.C. Group asserted claims against the company for breach of contract, which was settled during April 2024.

Related Party Transactions

• The company has a Sales and Marketing Consultant and Distribution Agreement with Kenek Brands Inc., owned by CEO Jack Ross.
• The lender under the Amended and Restated Loan Agreement is Knight Therapeutics (Barbados) Inc., and an affiliate of Knight is also the beneficial owner of approximately 19.6% of the company's outstanding common stock.
• The company has distribution agreements with Knight Therapeutics, Inc. for FOCUSfactor and Hand MD in Canada.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares in the IPO.
• Employees may benefit from the company's growth and expansion plans.
• Customers may see improvements in product offerings and availability.
• Suppliers and creditors may experience increased business opportunities with the company.

Next Steps

• The company will seek approval to list its common stock on the Nasdaq Capital Market.
• The company plans to expand its advertising strategy towards the end of 2024.
• The company plans to enter the Taiwan and Mexico markets in the second quarter of 2025 and in Australia and Asia in the first quarter of 2026.
• The company plans to introduce new graphics for the FOCUSfactor line in the third quarter of 2024.
• The company plans to introduce new complementary products to the Flat Tummy line-up in the fourth quarter of 2024.

Key Dates

Keywords

IPO, common stock, FOCUSfactor, Flat Tummy, underwriting, registration statement, financial results, consumer health, nutritional supplement, Roth Capital Partners